The concept of reducing cell-associated blood-borne viruses (BBVs) by filtration of the vector leukocytes from blood collected for transfusion has led to the development of high efficiency filters. Improved filtration technology demands newer methodology to accurately estimate the residual cells. We have developed an experimental model based on the hemocytometer counts and the polymerase chain reaction (PCR). performed on the lymphocytes derived from the units of red cell mass inoculated with marker cells (H9) persistently carrying cell-associated human immunodeficiency virus DNA (CA-HIV). We measured the effi-UMAN immunodeficiency virus (HIV), cytomegalovi-H rus (CMV), Epstein-Barr virus (EBV) and human T-cell leukemia virus-1 (HTLV-1) all known to be transmitted by cellular blood products, persist in leukocytes as latent infections. Removal of these vectors from blood by filtering out the leukocytes has been reported to (1) reduce the in vitro HIV-1 infectivity of blood,' (2) prevent serwonversion of CMV-negative persons transfused with blood from CMVpositive donors,* (3) prevent primary CMV infection in patients with hematologic malignan~ies,~ and (4) prevent transmission of HTLV-1 virus through blood t r a n s f~s i o n .~ Although bed-side leukocyte filters have been generally used to avoid febrile transfusion reactions, the putative benefits of preparing leukocyte-depleted blood for reducing alloimmunization, and most recently for reducing the transmission of transfusion-mediated virus diseases, have led to the development of newer filters capable of a six-log reduction of leukocytes. Reductions of this magnitude cannot be measured by conventional counting methods, including the recent method using propidium iodide staining that detects 11 leukocytes per microliter of blood.' This has led to the need for alternative approaches to assess filtration efficiency.
H rus (CMV), Epstein-Barr virus (EBV) and human
T-cell leukemia virus-1 (HTLV-1) all known to be transmitted by cellular blood products, persist in leukocytes as latent infections. Removal of these vectors from blood by filtering out the leukocytes has been reported to (1) reduce the in vitro HIV-1 infectivity of blood,' (2) prevent serwonversion of CMV-negative persons transfused with blood from CMVpositive donors,* (3) prevent primary CMV infection in patients with hematologic malignan~ies,~ and (4) prevent transmission of HTLV-1 virus through blood t r a n s f~s i o n .~ Although bed-side leukocyte filters have been generally used to avoid febrile transfusion reactions, the putative benefits of preparing leukocyte-depleted blood for reducing alloimmunization, and most recently for reducing the transmission of transfusion-mediated virus diseases, have led to the development of newer filters capable of a six-log reduction of leukocytes. Reductions of this magnitude cannot be measured by conventional counting methods, including the recent method using propidium iodide staining that detects 11 leukocytes per microliter of blood. ' This has led to the need for alternative approaches to assess filtration efficiency.
We have investigated the use of a cell-associated virus model that involves inoculation of HIV-infected lymphocytes into units of packed red cells as an independent marker. We estimated the efficiency of filtration by quantitating cellassociated HIV DNA (CA-HIV) in pre-and post-filtration concentrates using limiting-dilution titrations and gene amplification of HIV sequences by the polymerase chain reaction (PCR). Our model experimentally validates the hypothesis that biologic markers (nucleic acid) allow for more accurate and quantitative assessment of filter efficiency than do conventional automated or manual counting methods.
MATERIALS AND METHODS
Six anti-HIV negative blood units were selected from routinely screened normal blood donors accepted at the Irwin Memorial Blood Centers, San Francisco. Freshly drawn blood was collected in the CPD anticoagulant and processed according to standard procedures to make units of packed cells in ADSOL (Fenwal, Deerfield, IL). Units used in our experiments were obtained within 48 hours of blood collection. Before filtration, each of these units was inoculated with a predetermined number of cells containing CA-HIV.
HIV inoculum. CA-HIV inoculum was obtained from continuous cell line (H9), stably infected with HIV-1 (HTLVIIIB). Persistent infection of these cells was regularly confirmed by immunocytochemical detection of the p24 antigen in over 90% of the cells.6 Before inoculation into blood for filtration, the infected cells were washed 5 times in Hanks balanced salt solution to remove any cell-free HIV. Viable HIV infected cells were inoculated into the unit of blood prepared for filtration in a ratio of 1 cell to 100 total leukocytes counted in the unit of blood. The inoculated number of marker cells range between 1.14 x lo7 and 3 x lo7 with a mean of 2.07 x lo7 (log,, 7.25).
Filters. A prototype experimental filter (Pall Biomed Products Corporation, Glen Cove, NY) was used for the evaluation of concurrent removal of total leukocytes and the CA-HIV marker Cells.
Isolation, concentration, and enumeration of PBMCand CA-HIV from blood. After addition and adequate mixing of the CA-HIV inocula in the blood bag, 15.0 mL aliquot of blood was removed to obtain the pre-filtration sample. The entire volume of the filtered blood was divided into 15.0 mL aliquots and processed to recover the maximum possible residual cells. After mixing with an equal volume of Hanks, each 15.0 mL aliquot of both pre-and post-filtration samples was layered on 30.0 mL Lymphoprep (Robin Scientifics, Sunnyvale, CA). Following centrifugation, the erythrocytes and granulocytes were pelleted, while the peripheral blood mononuclear cells (PBMC) as well as the inoculated CA-HIV were concentrated as a single lymphocyte band in the Lymphoprep tube containing the prefiltration blood. No band was visible at the interface in the tubes containing the post-filtered blood. Therefore, about 10 mL of the interface fluid from each tube of post-filtered blood was pooled and centrifuged to recover any residual cells. Most of the supernatant was removed, leaving about 200 pL of the fluid containing any residual cells that were washed with 20.0 mL of Hanks, followed by centrifugation and resuspension in 1.0 mL Hanks. Similarly, cells
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concentrated from the pre-filtration sample were also washed and suspended in 1 .O mL Hanks. Thus, the cells from 15.0 mL aliquot of pre-filtration blood, as well as the residual cells from the entire post-filtration unit were concentrated into separate 1.0 mL cell suspensions. The purpose of concentrating PBMC from the filtered blood was to remove red cells, as well as plasma, that inhibit the detection of HIV-DNA by PCR.' The respective concentrates were then mixed with trypan blue stain for estimating the viable cells. Total counts were determined manually in a hemocytometer and corrected for the loss from Lymphoprep concentration. The reduction in the cell numbers was expressed as the difference between the log,, of corresponding pre-and post-filtration numbers of cells.
Quantitative detection of HIV-1 DNA by polymerase chain reaction (PCR). An aliquot of the concentrated cell suspension containing 1,000,000 cells from the pre-filtration sample was serially diluted in 10-fold steps in Hanks containing lo6 normal carrier PBMC. Half of the post-filtered cell suspension that typically had undetectable cells was similarly diluted in Hanks with lo6 carrier cells; the remainder was used for viability test using trypan blue stain. Lysates of the cell suspensions containing 250,000 cells were prepared for PCR-mediated DNA amplifications using the SK38/39 primer pairs, Taq polymerase, 30 cycles of amplification and liquid hybridization with '*P-labeled probes for the detection of amplified HIV gene products, as previously reported in detail. 8 The highest dilution of the cell concentrate giving a positive PCR signal was considered to contain 1 detectable unit of HIV-DNA, and is referred to hereafter as the polymerase chain reaction unit (PCRU). The number of PCRU/mL of blood was then calculated by dividing the number of PCRU/mL of the concentrate by the volume of blood used for the Lymphoprep concentration step. The numbers of residual PBMC in the filtered blood were estimated based on the assumption that the number of input PCRU per PBMC before filtration remained unchanged after filtration. Because neither Estimation of residual PBMC in the filtered blood.
PCRU nor PBMC were detectable in the post-filtered blood, the residual cell numbers were estimated to be less than the number of input PBMC corresponding to 1 PCRU in the prefiltration sample. The difference between log,, of input cells and log,, of the estimated PBMC in the filtered blood provided the log,, reduction of the number of PBMC as a measure of efficiency of the filter (see footnote to Table 1 for an example of calculations and derivations of the estimate).
RESULTS
The volume of blood used for the six experiments (Table 1) in the ratio of 1:lOO leukocytes, 1 PCRU corresponds to the detection of approximately 2,600 total leukocytes in a unit of blood.
Because PCRU and lymphocytes were undetectable in the filtered blood, we estimated that the total residual lymphocytes in the filtered blood (column D) was less than the number of lymphocytes corresponding to 1 PCRU detected in the blood before filtration (column C). In column E, we have expressed the estimated number of residual cells per milliliter, with a mean of less than 4.18 cells. We determined the filtration efficiency by subtracting the log,, of the estimated postfiltration lymphocyte counts shown in column D from the log,, of input lymphocytes shown in column A. The mean reduction in cells was greater than 5.84 2 0.07 logs.
DISCUSSION
To evaluate the performance of any leukocyte removal filter, one needs to determine the number of leukocytes entering the filter (input cells) and then enumerate the residual cells (output) in the filtered blood. The difference between these two counts would reflect the reduction caused by the filtration process. However, this simplistic derivation gets complicated when a filter yields an effluent that contains residual cells in too small a number to be reliably counted by automated cell counters or hemocytometers. Recently, flow cytometric analysis of propidium iodide stained cells has been shown to detect an average of 11,000 leukocytes per milliliter,5 which computes to 3,300 lymphocytes per milliliter, assuming that 30% of leukocytes are lymphocytes. Using HIV-DNA, we detected less than 4 lymphocytes per milliliter, offering a t least 825 times greater sensitivity than does the recently described propidium iodide staining method. The apparently higher sensitivity of our model possibly reflects the dual benefits of concentrating PBMC as well as amplifying the HIV-DNA in the marker cells carrying multiple copies of viral genome. This experimental approach enabled us to demonstrate that the prototype filter lowered the load of PBMC in blood by greater than 5.84 + 0.07 logs.
In each of the six filtration experiments the residual cells were below the detection limit of the hemocytometer. To investigate the potential use of a CA-HIV marker as a tool for quantitating very low concentrations of cells and consequently the efficiency of filtration, PCR provides a paradigm for future investigations and quality control for leukocyte filters.
As we had used 1 .O% CA-HIV marker cells in our earlier culture studies for in vitro biological amplification,' and had also standardized the biochemical amplification procedure of PCR for HIV DNA: we applied the principle of amplification of biochemical tracer to our model. The modeling approach has inherent advantage over other counting methods: despite certain obvious constraints. For example, the evaluation of different primer pairs for amplifying any gene is a prerequisite because of extreme variability in the PCR results with different primer pairs for the DNA sequence of a given gene. As a result of contemporary interest in optimising HIV detection, the selection of SK 38/39 primer pair over several other primer pairs has been propitiously established. Whether use of higher concentrations of CA-HIV would enhance the sensitivity of the model remains to be determined. Similarly, the amplification of constitutive cellular DNA segments (eg, HLA or albumin) may be a useful alternative to multiple copy gene markers (eg, HIV-DNA or Ah). Furthermore, coamplification of these markers merits investigation for future improvements in our experimental model.
